RYZOLT Drug Patent Profile

When do Ryzolt patents expire, and what generic alternatives are available?

Ryzolt is a drug marketed by Purdue Pharma and is included in one NDA.

The generic ingredient in RYZOLT is tramadol hydrochloride. There are thirty-six drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the tramadol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ryzolt

A generic version of RYZOLT was approved as tramadol hydrochloride by SUN PHARM INDS INC on June 19^th, 2002.

Summary for RYZOLT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	67
Clinical Trials:	1
Patent Applications:	2,793
What excipients (inactive ingredients) are in RYZOLT?	RYZOLT excipients list
DailyMed Link:	RYZOLT at DailyMed

Recent Clinical Trials for RYZOLT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical College of Wisconsin	Phase 2

See all RYZOLT clinical trials

Paragraph IV (Patent) Challenges for RYZOLT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RYZOLT	Extended-release Tablets	tramadol hydrochloride	100 mg, 200 mg and 300 mg	021745	1	2009-06-18

US Patents and Regulatory Information for RYZOLT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Purdue Pharma	RYZOLT	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021745-001	Dec 30, 2008		DISCN	Yes	No
Purdue Pharma	RYZOLT	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021745-002	Dec 30, 2008		DISCN	Yes	No
Purdue Pharma	RYZOLT	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021745-003	Dec 30, 2008		DISCN	Yes	No

Expired US Patents for RYZOLT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Purdue Pharma	RYZOLT	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021745-003	Dec 30, 2008
Purdue Pharma	RYZOLT	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021745-002	Dec 30, 2008
Purdue Pharma	RYZOLT	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021745-003	Dec 30, 2008
Purdue Pharma	RYZOLT	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021745-001	Dec 30, 2008
Purdue Pharma	RYZOLT	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021745-002	Dec 30, 2008
Purdue Pharma	RYZOLT	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021745-003	Dec 30, 2008

International Patents for RYZOLT

See the table below for patents covering RYZOLT around the world.

Country	Patent Number	Title	Estimated Expiration
India	178679	A method for preparing a sustained release tablet for oral adminstration
Canada	2125904	FORMULATIONS A LIBERATION-RETARD, REVETUES DE DISPERSIONS AQUEUSES D'ETHYLCELLULOSE (CONTROLLED RELEASE FORMULATIONS COATED WITH AQUEOUS DISPERSIONS OF ETHYLCELLULOSE)
Norway	320307
Slovakia	140694	PREPARATIONS WITH PERMANENT RELEASE OF EFFECTIVE COMPONENT AND METHOD OF THEIR PREPARATION
Israel	168114	SUSTAINED-RELEASE TRAMADOL FORMULATIONS AND A TABLET CONTAINING SAME
Singapore	50706	Sustained release compositions and a method of preparing pharmaceutical compositions

Supplementary Protection Certificates for RYZOLT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0566709	SPC/GB04/012	United Kingdom		PRODUCT NAME: TRAMADOL HYDROCHLORIDE, PARACETAMOL; REGISTERED: FR NL 25970 20020405; UK PL 00242/0384 20030925
2488169	C202330042	Spain		PRODUCT NAME: COCRISTAL DE TRAMADOL, OPCIONALMENTE EN FORMA DE UNA SAL FISIOLOGICAMENTE ACEPTABLE, Y CELECOXIB; NATIONAL AUTHORISATION NUMBER: 89051; DATE OF AUTHORISATION: 20230925; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 89051; DATE OF FIRST AUTHORISATION IN EEA: 20230925
0566709	C300152	Netherlands		PRODUCT NAME: TRAMADOLI HYDROCHLORIDUM EN PARACETAMOLUM; NAT. REGISTRATION NO/DATE: RVG 28113 20030115; FIRST REGISTRATION: 359 228-3 2002050405

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug RYZOLT

Last updated: July 29, 2025

---

Introduction

Ryzolt (generic name: tramadol ER) is an extended-release formulation of tramadol, an opioid analgesic indicated primarily for managing moderate to moderately severe chronic pain. As pain management remains a lucrative segment within the pharmaceutical industry, understanding the market dynamics and financial trajectory of Ryzolt is vital for stakeholders—including manufacturers, investors, and healthcare policymakers.

This analysis provides a comprehensive overview of the current market environment, competitive positioning, regulatory landscape, and future financial prospects for Ryzolt.

---

Market Overview and Segmentation

Global Pain Management Market

The pain management market was valued at approximately USD 20 billion in 2022 and is projected to reach USD 30 billion by 2030, with a CAGR of around 5.2% (2023–2030), driven by rising chronic pain prevalence, aging populations, and ongoing opioid prescription practices. The opioid analgesics segment, which includes tramadol-based drugs like Ryzolt, constitutes a significant share within this broader market.

Ryzolt’s Positioning

Ryzolt, marketed by Johnson & Johnson under the brand name Ultram ER and in some markets as Ryzolt (as a generic), targets patients requiring long-term pain relief. It offers advantages over immediate-release formulations—such as improved compliance and steady plasma levels—making it attractive in chronic pain management.

---

Market Dynamics Influencing RYZOLT

Demand Drivers

1. Chronic Pain Prevalence: Globally, chronic pain affects over 1.5 billion individuals, emphasizing demand for effective long-term analgesics. Ryzolt addresses this segment with its extended-release profile, reducing dosing frequency and improving patient adherence.

2. Aging Populations: Countries like the US, Japan, and many European nations experience aging demographics prone to chronic pain-related conditions including osteoarthritis, neuropathy, and fibromyalgia, which boost demand for sustained-release opioids.

3. Prescribing Trends: While opioid prescribing has faced scrutiny, clinicians continue to prescribe cautiously optimized formulations like Ryzolt for suitable patients, balancing pain relief with minimizing abuse potential.

Supply Chain and Manufacturing Factors

• Ryzolt benefits from Johnson & Johnson’s established manufacturing and distribution channels, ensuring wide accessibility.
• The generic market expansion has increased Ryzolt’s availability, reducing costs and enhancing market penetration.

Regulatory and Legal Environment

• The opioid landscape is fraught with regulatory challenges. Increased scrutiny over opioid prescriptions, potential for abuse, and subsequent regulatory restrictions could adversely influence Ryzolt’s market potential.
• However, abuse-deterrent formulations and tighter prescribing guidelines aim to mitigate these concerns and affirm the market’s long-term stability.

---

Competitive Landscape

Major Competitors

• Immediate-Release Tramadol: Cheaper and more widely used; however, less effective for sustained pain relief.
• Other Extended-Release Opioids: Such as morphine ER, oxycodone ER, and fentanyl patches, which compete on efficacy but often come with higher costs and regulatory scrutiny.
• Non-Opioid Alternatives: Gabapentinoids, NSAIDs, and emerging biologics serve as competitive alternatives depending on specific patient needs.

Generic Market Penetration

The expiration of key patents related to Ryzolt’s formulations and patents for brand-name tramsol ER has fostered a growing generic market, decreasing costs and expanding access.

Market Challenges

• Rising opioid addiction concerns have led to tighter regulations, prescription monitoring, and provider hesitancy.
• Public and governmental pushback against opioids could limit prescription volumes, impacting revenue streams.

---

Financial Trajectory and Revenue Outlook

Historical Performance

• Johnson & Johnson historically recorded revenues of approximately USD 50 million annually from Ryzolt, though this has declined post-generic entry and increased regulatory constraints.
• The generic landscape has driven downward price pressures, compressing margins.

Forecasted Growth

• The extended-release opioids market is expected to grow modestly, with a projected CAGR of around 3% through 2030, influenced by steady demand for effective pain management.
• Ryzolt’s revenues are likely to decline initially due to generic competition but could stabilize or grow minimally if differentiated formulations or abuse-deterrent mechanisms are introduced.

Market Entry Strategies and Innovation

• Formulation Enhancements: Developing abuse-deterrent formulations to comply with regulatory trends.
• Pricing Strategies: Competitive pricing in the generics space to maintain market share.
• Geographical Expansion: Targeting emerging markets with rising chronic pain cases.

Risks to Financial Performance

• Regulatory restrictions reducing prescriptions.
• Increased competition from new non-opioid analgesics.
• Litigation and liability related to opioid use.

---

Regulatory Trends and Their Impact

• US FDA: Tightening of guidelines around opioid prescribing, with emphasis on abuse-deterrent medications.
• EMA and Other Agencies: Enhanced monitoring and restrictions could limit access in European markets.
• Legal Proceedings: Ongoing opioid litigation may affect development and marketing strategies for opioid formulations like Ryzolt.

---

Conclusion: Future Outlook

While Ryzolt remains a relevant product in the pain management spectrum, its financial trajectory faces headwinds from market saturation, regulatory constraints, and increasing generic competition. Nonetheless, strategic innovations—such as abuse-deterrent technologies—and expansion into emerging markets could sustain moderate revenues in niche segments. Long-term growth prospects hinge on adaptive regulatory compliance, portfolio diversification, and targeted marketing efforts.

---

Key Takeaways

• Market Position: Ryzolt occupies a stable niche in extended-release opioid analgesics, with steady demand driven by aging populations and chronic pain prevalence.
• Growth Challenges: Patent expiry, regulatory scrutiny, and competition from generics pose significant downside risks to revenue.
• Innovation Opportunities: Developing abuse-deterrent formulations and expanding into emerging markets can offset declining brand-name sales.
• Regulatory Landscape: Increasing restrictions on opioids necessitate strategic adaptations, including formulation improvements and responsible prescribing initiatives.
• Financial Outlook: Expect modest growth or stabilization, contingent on successful innovation and market expansion strategies amid ongoing market pressures.

---

Frequently Asked Questions (FAQs)

1. How does Ryzolt compare to other extended-release opioids in terms of market share?
Ryzolt's market share is relatively modest compared to larger players like OxyContin or fentanyl patches, primarily due to patent expirations and increased generic competition. Its niche positioning is more prominent in specific patient populations requiring long-term pain management with a focus on safety.

2. What are the primary regulatory concerns affecting Ryzolt’s future sales?
Regulatory agencies focus on opioid misuse, diversion, and abuse potential. Policies favor abuse-deterrent formulations and tighter prescription controls, which could limit Ryzolt’s prescribing in certain markets.

3. Are there prospects for Ryzolt to evolve into a non-opioid pain management solution?
While currently focused on opioid formulations, pharmaceutical companies are investing in non-opioid analgesics. Reformulation into non-addictive variants is unlikely in the short term but could be a future strategic aim.

4. How does the global shift towards opioid prescribing restrictions impact Ryzolt?
In markets like the US and Europe, escalating restrictions reduce prescribing volumes, potentially diminishing Ryzolt's revenue. However, continued demand persists where opioids remain authorized, especially for severe, chronic pain.

5. What role does Ryzolt play in Johnson & Johnson’s overall pain management portfolio?
Ryzolt complements J&J’s broader opioid portfolio by targeting patients needing extended-release formulations but represents a smaller fraction of the company's pain management revenues due to patent expirations and competition.

---

Citations

[1] MarketsandMarkets. Pain Management Market by Product, Application, and Region – Global Forecast to 2030.
[2] IQVIA. Global Opioid Use Trends.
[3] FDA. Guidance for Industry: Abuse-Deterrent Opioids – Evaluation and Labeling.
[4] Statista. Pain Management Market Revenue and Growth Rates.
[5] Johnson & Johnson Annual Reports.